Medullary Thyroid Cancer (MTC)
from OrphaChat — a Rare Disease Podcast Hosted by RCH
These sources collectively examine the clinical landscape of medullary thyroid cancer (MTC) and RET fusion-positive non-small-cell lung cancer (NSCLC), focusing on targeted therapeutic interventions. Research highlights the efficacy of selpercatinib, a selective tyrosine kinase inhibitor that has demonstrated significant antitumor activity and durable response rates in both previously treated and treatment-naive patients. While these medications offer a primary defense against RET-altered malignancies, emerging data also address the challenge of acquired resistance caused by specific genetic mutations. Complementing these clinical findings, the American Thyroid Association provides evidence-based guidelines for surgical management, diagnostic screening, and the biochemical monitoring of calcitonin levels. Furthermore, international resources like Orphanet and GARD offer specialized support and registry data for managing these rare diseases within a coordinated healthcare framework.
Embed this episode
No transcript yet.